Berardinelli-Seip syndrome: highlight of treatment challenge

BMJ Case Rep. 2013 Jan 28:2013:bcr2012007734. doi: 10.1136/bcr-2012-007734.

Abstract

Berardinelli-Seip congenital lipodystrophy (BSCL) syndrome is a rare autosomal-recessive disease characterised by lipoatrophy and associated with deregulations of glycidic and lipid metabolism. We report three BSCL cases with its typical clinical picture and complications. Clinically, they all show marked atrophy of adipose tissue, acromegaly, acanthosis nigricans and tall stature. Two cases present attention deficit hyperactivity and developmental learning disorders; another patient has hypertrophic myocardiopathy and polycystic ovary syndrome. In all the cases AGPAT2 was the identified mutation. All the cases present hypertriglyceridemia. One case has developed hyperinsulinism controlled with metformin and another case already has type 2 diabetes with a difficult clinical control. There is no curative treatment and the current treatment options are based only on symptomatic control of the complications. Recently, published studies showed that leptin-replacement therapy appears a promising tool in the metabolic correction of BSCL complications, highlighting the importance of further investigations in BSCL treatment.

Publication types

  • Case Reports

MeSH terms

  • Acanthosis Nigricans / etiology
  • Acromegaly / etiology
  • Acyltransferases / genetics
  • Child
  • Female
  • Humans
  • Hyperinsulinism / etiology
  • Hypertriglyceridemia / etiology
  • Lipodystrophy, Congenital Generalized / complications
  • Lipodystrophy, Congenital Generalized / genetics
  • Lipodystrophy, Congenital Generalized / therapy*
  • Male
  • Pedigree
  • Young Adult

Substances

  • Acyltransferases
  • 2-acylglycerophosphate acyltransferase